Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs

Carcinogenesis

Volumn 27, Issue 12, 2006, Pages 2434-2441

  Chen, Xian Cheng ^a,b   Wang, Rui ^a   Zhao, Xia ^a   Wei, Yu Quan ^b   Hu, Min ^a   Wang, Yang Sheng ^a   Zhang, Xiao Wei ^a   Zhang, Ru ^a   Zhang, Lin ^a   Yao, Bin ^a   Wang, Lian ^a   Jia, Yong Qian ^a   Zeng, Ting Ting ^a   Yang, Jin Liang ^a   Tian, Ling ^a   Kan, Bing ^a   Lin, Xiao Juan ^b   Lei, Song ^a   Deng, Hong Xin ^a   Wen, Yan Jun ^a   Mao, Yong Qiu ^a   Li, Jiong ^a   more..

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 12;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT DISORDER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CELL BASED GENE THERAPY; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; FEMALE; GENETIC ENGINEERING; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ULCER; VIRAL GENE DELIVERY SYSTEM; WEIGHT REDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENETIC ENGINEERING; INTERLEUKIN-12; LIVER NEOPLASMS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MESENCHYMAL STEM CELLS; MICE;

EID: 33845349814     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl069     Document Type: Article

References (55)

1. Cowen,R.L., Williams,K.J., Chinje,E.C., Jaffar,M., Sheppard,F.C.D., Telfer,B.A., Wind,N.S. and Stratford,I.J. (2004) Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: Reversing tumor radioresistance and effecting cure. Cancer Res., 64, 1396-1402.
2. Martenson,J.A., Willett,C.G., Sargent,D.J. et al. (2004) Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol. J. Clin. Oncol., 22, 3277-3283.
3. Malaisrie,S.C., Untch,B., Aranha,G.V., Mohideen,N., Hantel,A. and Pickleman,J. (2004) Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: Experience at a single institution. Arch. Surg., 139, 532-539.
4. Spiro,S.G. and Silvestri,G.A. (2005) One hundred years of lung cancer. Am. J. Respir. Crit. Care Med., 172, 523-529.
5. Mulshine,J.M. (2005) Clinical issues in the management of early lung cancer. Clin. Cancer Res., 11, 4993-4998.
6. Meyskens,F.L. Jr, Surwit,E., Moon,T.E. et al. (1994) Enhancement of regression of cervical intraepithelial neoplasia II (moderate.dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J. Natl Cancer Inst., 86, 539-543.
7. Lippman,S.M., Batsalis,J.G., Toth,B.B. et al. (1993) Comparison of lowdose isotretinoin with beta-carotene to prevent oral carcinogenesis. N. Engl. J. Med., 328, 15-20.
8. Meyskens,F.L.Jr, Gerner,E.W., Emerson,S. et al. (1998) Effect of difluoromethylornithine on rectal mucosal levels of polyamines in a randomized double-blind trial for colon cancer prevention. J. Natl Cancer Inst., 90, 1212-1218.
9. Nicoletti,B.K.G., Carlo,E.D., Cavallo,F., Landuzzi,L., Melani,C., Giovarelli,M., Rossi,I., Nanni,P. and Giovanni,C.D. (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med., 188, 589-596.
10. Nanni,P., Nicoletti,G., Giovanni,C.D. et al. (2001) Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in her-2/neu transgenic mice. J. Exp. Med., 194, 1195-1206.
11. Curt,A., Parenza,M. and Colombo,M.P. (2003) Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood, 101, 568-575.
12. Liu,J.G., Xiang,Z.Y. and Ma,X.J. (2004) (Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-Nnitrosourea- induced T lymphoma. J. Immunol., 173, 1184-1193.
13. Tsao,A.S., Edward,S., Kim,E.S. and Hong,W.K. (2004) Chemoprevention of cancer. CA Cancer J. Clin., 54, 150-180.
14. Goodin,S. and Shiff,S.J. (2004) NSAIDs for the chemoprevention of oral cancer: Promise or pessimism? Clin. Cancer Res., 10, 1561-1564.
15. Van Damme,A., Vanden Driessche,T. and Collen,D. (2002) Bone marrow stromal cells as targets for gene therapy. Curr. Gene Ther., 2, 195-209.
16. Hung,S.C., Deng,W.P., Yang,W.K. et al. (2005) Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin. Cancer Res., 11, 7749-7756.
17. Shrayer,D.P., Bogaars,H., Cole,B., Wolf,S.F. and Wanebo,H.J. (2002) Capacity of murine IL-12 to inhibit the development of primary melanoma tumors and to prevent lung metastases in the melanomachallenged mice. J. Exp. Thera. Oncol., 2, 93-102.
18. Yoon,T.J., Yoo,Y.C., Kang,T.B., Song,S.K., Lee,K.B., Her,E., Song,K.S. and Kim,J.B. (2003) Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch. Pharm. Res., 26, 861-867.
19. Wang,Z., Qiu,S.J., Ye,S.L., Tang,Z.Y. and Xiao,X. (2001) Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Ther., 8, 751-758.
20. He,T.C., Zhou,S., Costa,L.T.D., Yu,J., Kinzler,K.W. and Vogelstein,B.A. (1998) simplified system for generating recombinant adenoviruses. Proc. Natl Acad. Sci. USA, 95, 2509-2514.
21. Peister,A., Mellad,J.A., Larson,B.L., Hall,B.M., Gibson,L.F. and Prockop,D.J. (2004) Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood, 103, 1662-1668.
22. Fischer,A.H., Taysavang,P. and Jhiang,S.M. (2003) Nuclear envelope irregularity is induced by RET/PTC during interphase. Am. J. Pathol., 163, 1091-1100.
23. Hiraoka,K., Yamamoto,S., Otsuru,S., Nakai,S., Tamai,K., Morishita,R., Ogihara,T. and Kaneda,Y. (2004) Enhanced tumor-specific long-term immunity of hemaggluttinating virus of Japan-mediated dendritic celltumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol., 173, 4297-4307.
24. Ebert,O., Harbaran,S., Shinozaki,K. and Woo,S.L. (2005) Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Thera., 12, 350-358.
25. Finn,O.J. (2003) Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol., 3, 630-641.
26. Lollini,P.L. and Forni,G. (2003) Cancer immunoprevention: Tracking down persistent tumor antigens. Trends Immunol., 24, 62-66.
27. Finn,O.J. and Forni,G. (2002) Prophylactic cancer vaccines. Curr. Opin. Immunol., 14, 172-177.
28. Lollini,P.L. and Forni,G. (2002) Antitumor vaccines: Is it possible to prevent a tumor? Cancer Immunol. Immunother., 51, 409-416.
29. Forni,G., Lollini,P.L., Musiani,P. and Colombo,M.P. (2000) Immunoprevention of cancer: Is the time ripe? Cancer Res., 60, 2571-2575.
30. Kobayashi,M., Fitz,L., Ryan,M., Hewick,R.M., Clark,S.C., Chan,S., Loudon,R., Sherman,R., Perussia,B. and Trinchieri,G. (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med., 170, 827-845.
31. Wolf,S.F., Temple,P.A., Kobayashi,M. et al. (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol., 146, 3074-3081.
32. Trinchieri,G. and Gerosa,F. (1996) Immunoregulation by interleukin-12. J. Leukocyte Biol., 59, 505-511.
33. Fan,H., Walters,C.S., Dunston,G.M. and Tackey,R. (2002) IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. Cytokine, 19, 126-137.
34. Cohen,J.E(1995) Clinical trials: IL-12 deaths: explanation and a puzzle. Science, 270, 908.
35. Serakinci,N., Guldberg,P., Burns,J.S., Abdallah,B., Schrodder,H., Jensen,T. and Kassem,M. (2004) Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene, 23, 5095-5098.
36. Isner,J.M. and Asahara,T. (1999) Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest., 103, 1231-1236.
37. Studeny,M., Marini,F.C., Champlin,R.E., Zompetta,C., Fidler,I.J. and Andreeff,M. (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumor. Cancer Res., 62, 3603-3608.
38. Deans,R.J. and Moseley,A.B. (2000) Mesenchymal stem cells: Biology and potential clinical uses. Exp. Hematol., 28, 875-884.
39. Nastala,C.L., Edington,H.D., McKinney,T.G. et al. (1994) Recombinant IL-12 administration induces tumor regression in associated with IFN-production. J. Immunol., 153, 1697-1706.
40. Fernandez,N.C., Levraud,J.P., Haddada,H., Perricaudet,M. and Kourilsky,P. (1999) High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J. Immunol., 162, 609-617.
41. Saffran,D.C., Horton,H.M., Yankauchas,M.A., Anderson,D., Barnhart,K.M., Abai,A.M., Hobart,P., Manthorpe,M., Norman,J.A. and Parker,S.E. (1998) Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: Induction of CD8+ T-cell immunity. Cancer Gene Ther., 5, 321-330.
42. Rakhmilevich,A.L., Turner,J., Ford,M.J., McCabe,D., Sun,W.H., Sondel,P.M., Grota,K. and Yang,N.-S. (1996) Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Natl Acad. Sci. USA, 93, 6291-6296.
43. Tannenbaum,C.S., Tubbs,R., Armstrong,D., Finke,J.H., Bukowski,R.M. and Hamilton,T.A. (1998) The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol., 161, 927-932.
44. Lode,H.N., Dreier,T., Xiang,R., Varki,N.M., Kang,A.S. and Reisfeld,R.A. (1998) Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc. Natl Acad. Sci. USA, 95, 2475-2480.
45. Tannenbaum,C.S., Wicker,N., Armstrong,D., Tubbs,R., Finke,J., Bukowski,R.M. and Hamilton,T.A. (1996) Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol., 156, 693-699.
46. Alatrash,G., Hutson,T.E., Molto,L. et al. (2004) Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J. Clin. Oncol., 22, 2891-2900.
47. Gately,M.K., Warrier,R.R. and Honasoge,S. (1994) Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN- in vivo. Int. Immunol., 6, 157-167.
48. Manetti,R., Gerosa,F. and Giudizi,M.G. (1994) Interleukin 12 induces stable priming for interferon (IFN-) producing during differentiation of human T helper (Th) cells and transient IFN- production in established Th2 cells clones. J. Exp. Med., 179, 1273-1283.
49. Wigginton,J.M., Park,J.W., Gruys,M.E. et al. (2001) Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/ pulse IL-2: Induction of local T cell infiltration, fas/fas ligand gene expression, and mammary epithelial apoptosis. J. Immunol., 166, 1156-1168.
50. Nakagawa,R., Nagafune,I., Tazunoki,Y. et al. (2001) Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J. Immunol., 166, 6578-6584.
51. Yao,L., Sgadari,C., Furuke,K., Bloom,E.T., Teruya-Feldstein,J. and Tosato,G. (1999) Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood, 93, 1612-1621.
52. Voest,E.E., Kenyon,B.M., O'Reilly,M.S., Truitt,G., D'Amato,R.J. and Folkman,J. (1995) Inhibition of angiogenesis in vivo by interleukin 12. J. Natl Cancer Inst., 87, 581-586.
53. Hess,S.D., Egilmez,N.K., Bailey,N. et al. (2003) Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J. Immunol., 170, 400-412.
54. Nakayama,Y., Inoue,Y., Nagashima,N. et al. (2004) Relationships between local and systemic expression of interleukin-12 and plasma levels of vascular endothelial growth factor in patients with gastric cancer. Anticancer Res., 24, 3289-3294.
55. Broderick,L., Yokota,S.J., Reineke,J. and Mathiowitz,E. (2005) Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-, and eradicate tumor cells. J. Immunol., 174, 898-906.